

## Leading Physician to Chair Clinical Advisory Committee

**SYDNEY, Australia, 3 June 2019:** Recce Pharmaceuticals Ltd (ASX: RCE) (**Company**), the company developing a new class of synthetic antibiotics, today announced the formation of a Clinical Advisory Committee to assist in the Board's growing clinical considerations under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).

The new Clinical Advisory Committee will be chaired by Dr David Bowers, Spinal Injury Physician at Royal North Shore and other University Hospitals in Sydney.

Dr Bowers has a specialist interest in the treatment of complex and life-threatening antibiotic resistant infections, particularly among patients with severe spinal cord injuries.

Recce Pharmaceuticals Executive Chairman Dr Graham Melrose said, "Dr Bowers experience will significantly enhance the insights we receive from the new committee as we advance our new antibiotic product pipeline into the clinic."

Independent to the Company, Dr Bowers has not accepted any remuneration for his valued contributions to date and will continue on this basis in the now formalised role.

### About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-human clinical trials.



ASX: RCE

**Head Office** Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

**R&D Centre - Perth** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

**Washington Office** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA